Minister of Health and Social Protection, Amin Al-Tahrawi, has denied allegations regarding irregularities in drug procurement, emphasizing that all procurement processes are subject to strict oversight. He called for an elevation of public discourse free from speculations that “do not serve the citizen or the nation,” asserting that transparency is paramount, thereby preventing any individual decisions.
Al-Tahrawi’s statements came during a meeting of the Social Sectors Committee in the House of Representatives held on Wednesday to discuss concerns raised about drug procurement. He underscored that institutional dialogue remains the most suitable framework for addressing matters related to public contracts and conflicts of interest, considering his attendance at the committee as a “clear message that the ministry hides nothing.”
He highlighted the legal and regulatory procedures governing drug procurement operations, clarifying that these are conducted exclusively in accordance with established regulations and are publicly announced on the national public procurement portal. These operations undergo close scrutiny by relevant departments within the Ministry of Economy and Finance. He asserted that these mechanisms keep procurement decisions “free from personal interpretations or individual initiatives.”
Regarding claims about a contract for supplying potassium, the minister clarified that the contract was awarded to a local production company under a transparent bidding process, unequivocally denying any rumors linking it to an imported company with a temporary license.
On the topic of conflicts of interest, Al-Tahrawi reiterated that contracts are made with companies governed by commercial law rather than individuals. He pointed out that enhancing the legal framework governing this area remains a “collective legislative project” that Parliament is empowered to develop. He reaffirmed the administration’s commitment to adhere strictly to existing laws without exception.
The minister indicated that reforming the health system constitutes a “national strategic project,” explaining that the government has worked on implementing previous oversight recommendations by establishing the “National Agency for Medicines and Health Products” as mandated by Law 22.10.
Al-Tahrawi concluded that the agency is now responsible for enhancing pharmaceutical sovereignty and ensuring a regular supply of medications while adopting a modern and independent governance structure with stringent technical standards. He emphasized that the agency’s director general is the legally authorized individual to grant licenses and oversee technical procedures.
